164 related articles for article (PubMed ID: 37012292)
1. The structure of the hematopoietic system can explain chronic myeloid leukemia progression.
Pérez-Jiménez M; Derényi I; Szöllősi GJ
Sci Rep; 2023 Apr; 13(1):5411. PubMed ID: 37012292
[TBL] [Abstract][Full Text] [Related]
2. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation.
Tachibana T; Kondo T; Uchida N; Doki N; Takada S; Takahashi S; Yano S; Mori T; Kohno A; Kimura T; Fukuda T; Atsuta Y; Nagamura-Inoue T;
Transplant Cell Ther; 2022 Jun; 28(6):321.e1-321.e8. PubMed ID: 35296447
[TBL] [Abstract][Full Text] [Related]
4. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
5. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
6. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Singh MM; Howard A; Irwin ME; Gao Y; Lu X; Multani A; Chandra J
PLoS One; 2012; 7(12):e51611. PubMed ID: 23284724
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
8. A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
Koch D; Eisinger RS; Gebharter A
J Theor Biol; 2017 Nov; 433():94-105. PubMed ID: 28870619
[TBL] [Abstract][Full Text] [Related]
9. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
10. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
11. A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.
Wang Z; Chen W
Methods Mol Biol; 2016; 1465():149-57. PubMed ID: 27581146
[TBL] [Abstract][Full Text] [Related]
12. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
13. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
14. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?
Rumpold H; Webersinke G
Curr Cancer Drug Targets; 2011 Jan; 11(1):3-19. PubMed ID: 21062244
[TBL] [Abstract][Full Text] [Related]
16. Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.
Gotoh M; Tauchi T; Yoshizawa S; Kitahara T; Kiguchi T; Kimura Y; Ohyashiki K
Int J Hematol; 2010 Jan; 91(1):128-31. PubMed ID: 20047099
[TBL] [Abstract][Full Text] [Related]
17. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
18. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
[TBL] [Abstract][Full Text] [Related]
19. A Case of Childhood Blastic Phase Chronic Myeloid Leukemia With Minor BCR-ABL.
Yamanaka J; Shimizu M; Sato M; Inoue M; Matsui M; Shimada H; Shichino H
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e459-e462. PubMed ID: 30994506
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
